Human NMN trials have used daily doses between 250 mg and 1,200 mg, and the lower end of that range produced the clearest functional result. In the guides we publish here, NMN dosing is where product marketing and trial evidence diverge most sharply, because the doses on the shelf were set by what a capsule can hold and what a price point can bear.
The trial that found improved muscle insulin sensitivity used 250 mg a day. The trial that used 1,200 mg did not clearly outperform its own 600 mg arm. Neither of those facts appears on a product page recommending you escalate.
The Verdict
The Doses Each Trial Gave
Four human trials carry the dosing discussion, and reading what each one administered is more useful than reading any label.
| Trial | Daily dose | Duration | What was measured | What to note |
|---|---|---|---|---|
| Irie et al. 2020 | 100, 250 and 500 mg | Single dose | Acute tolerability and blood chemistry | Ten healthy men. Establishes that a single dose is tolerated and nothing more |
| Yoshino et al. 2021, Science | 250 mg daily | 10 weeks | Skeletal muscle insulin sensitivity improved | The lowest daily dose with a positive functional finding, in 25 postmenopausal women with prediabetes |
| Liao et al. 2021 | 300, 600 and 1,200 mg daily | 6 weeks | Aerobic capacity measures in amateur runners | The highest dose studied. Improvements were reported at the higher doses alongside exercise training |
| Yi et al. 2023 | 300, 600 and 900 mg daily | 60 days | Blood NAD+ rose with dose. Walking distance and a subjective fatigue score improved | The longest of the commonly cited trials, and the clearest dose-response signal for the NAD+ marker |
Two rows deserve reading together. Yoshino and colleagues found a functional improvement at 250 mg over ten weeks in a group selected for prediabetes. Yi and colleagues found blood NAD+ rising with dose to 900 mg over 60 days, alongside modest changes in walking distance and a fatigue score.
Those are different endpoints in different populations, which is the recurring difficulty with this category. A dose that moves a marker is not automatically a dose that changes a person, and our NMN versus NR comparison covers why that gap matters here more than in most supplement categories.
How Product Labels Compare
Commercial NMN products typically carry 250 mg, 500 mg or 1,000 mg per serving. The 500 mg tier is the most common, which places it above the dose with the best functional evidence and below the dose with the clearest NAD+ response.
Two label practices are worth checking before comparing prices.
- Serving size versus capsule size. A bottle advertising 1,000 mg often means two capsules of 500 mg, which halves the count you get for the price.
- Blends that dilute the NMN. Products combining NMN with resveratrol, TMG or quercetin frequently carry less NMN than the front label implies. The supplement facts panel gives the actual figure.
Price per gram of NMN is the comparison that survives both practices, and it is rarely the number a brand puts in front of you.
When to Take It, and Whether Timing Matters
Morning dosing is the standard recommendation and no human trial has tested it against any alternative. The rationale comes from NAD+ following a circadian rhythm that peaks during the active phase, observed largely in animal work.
That is a mechanism rather than a finding. No trial has compared morning against evening administration on blood NAD+, on sleep, or on any functional endpoint. The practical advice that survives is unglamorous: take it at whatever time you will actually remember, since adherence over eight weeks affects the outcome more than an untested schedule.
Food is the same story. Trials used both, none compared them, and the only reason to prefer taking it with a meal is that nausea is the most commonly reported mild effect and it is less likely on a full stomach. Our page on NMN side effects covers what the trials reported.
How Long Before Anything Changes
Blood NAD+ rises within days to weeks. Everything else in the trials took longer.
- NAD+ in blood. Days to weeks, dose-dependent, and not measurable outside a research setting.
- Subjective fatigue and walking distance. 60 days in the trial that measured them.
- Muscle insulin sensitivity. 10 weeks in the trial that found it.
Eight to ten weeks is therefore the shortest sensible evaluation period, and it comes with a difficulty specific to this category. There is no routine clinical NAD+ assay with established reference ranges, so you cannot check whether your dose is doing the thing you bought it for. That leaves subjective assessment over a two-month window, which is exactly the setup where placebo effects are strongest.
Sublingual, Liposomal and the Delivery Claims
Sublingual tablets, liposomal capsules and powdered formats all claim better absorption than a standard capsule. None has been compared against oral NMN in a human trial.
Every trial in the table above used oral administration, which means the entire evidence base for NMN was generated with the format the premium products claim to improve on. Paying more for a delivery route with no comparative data, inside a category where the underlying benefit is itself unsettled, compounds one uncertainty with another.
Where extra money does buy something is testing. A batch-specific certificate of analysis from an independent laboratory tells you the capsule contains the NMN on the label, which is a real risk in a category that spent three years in regulatory limbo in the United States.
Whether You Need TMG Alongside It
Trimethylglycine is sold as a companion on the theory that NAD+ metabolism consumes methyl groups and could deplete them over time. It is a coherent mechanism with no human evidence attached.
No trial has demonstrated methyl depletion from NMN supplementation, and none has tested whether adding TMG changes any endpoint. Anyone genuinely concerned about methylation status has a better option available: homocysteine is a routine blood test with established reference ranges, and it responds to methyl group availability. Measuring it costs less than a year of TMG.
Who Should Not Take a Higher Dose
Three groups should stay at the low end or ask a clinician before starting.
- Anyone with an active cancer diagnosis or under surveillance. The NAD+ mechanism runs opposite to an experimental anticancer drug class, and dose escalation makes that question larger rather than smaller.
- Anyone with liver or kidney disease. Trial participants were largely healthy, so the dose-tolerance findings do not extend to impaired clearance.
- Anyone taking NMN for a specific measurable goal. If your target is insulin sensitivity, the trial evidence sits at 250 mg, and our page on fasting insulin covers a marker you can actually track to see whether it worked.
Our reading would change if a dose-ranging trial ran 250 mg against 1,000 mg for a year with a functional primary endpoint. The current evidence has different doses attached to different outcomes in different populations, which makes any dose recommendation an inference rather than a finding. A direct comparison would replace the guesswork on every product page in this category, including this one.
If you are starting NMN, buy the 250 mg product with a published certificate of analysis, take it at the same time each day, and give it ten weeks before deciding whether the NMN dosage is worth the money.
Frequently Asked Questions
How much NMN should I take per day?
The studied range runs from 250 mg to 1,200 mg daily, and 250 to 600 mg covers most of the trials that reported a functional change alongside the NAD+ rise. Starting at 250 mg and holding it for eight weeks is a defensible approach, because it is the lowest dose with a positive human finding behind it and because the dose-response evidence above 600 mg is limited to two trials. Going above 900 mg means going outside what has been examined.
When is the best time to take NMN?
Morning is the conventional recommendation, and the evidence for it is weak. The rationale rests on NAD+ following a circadian rhythm that peaks during the active phase, which is a real observation in animal work rather than a tested dosing schedule in people. No human trial has compared morning against evening dosing on any endpoint. Taking it at a time you will remember is a stronger argument than any timing mechanism currently on offer.
Should NMN be taken with or without food?
Trials have used both and none compared them, so there is no evidence-based answer. The practical consideration is tolerability: nausea is the most commonly reported mild effect and it is more likely on an empty stomach. If you get any stomach discomfort, take it with breakfast. If you do not, either works and it is not worth optimising a variable no trial has measured.
How long does NMN take to work?
Blood NAD+ rises within days to weeks, and it is the only thing that reliably changes on that timescale. Functional endpoints in the trials that found them took longer: the muscle insulin sensitivity finding came at 10 weeks, and the walking distance and fatigue findings at 60 days. If you are judging NMN by how you feel, eight weeks is the shortest evaluation window worth trusting. If you are judging it by a blood NAD+ measurement, there is no routine clinical assay to do so.
Is more NMN better?
Blood NAD+ rises with dose across the studied range, and whether anything downstream improves in proportion has not been shown. The 250 mg arm in the Science trial produced a functional finding, and the 1,200 mg arm in the running trial did not clearly outperform 600 mg on its primary endpoints. Dose escalation above 900 mg has no supporting data in either direction, which makes it a cost increase with an unstudied risk profile attached.
Do I need to take TMG with NMN?
Trimethylglycine is sold alongside NMN on the theory that NAD+ metabolism consumes methyl groups and could deplete them. No human trial has demonstrated methyl depletion from NMN supplementation, and no trial has tested whether adding TMG changes any outcome. It is a mechanistically plausible precaution with no evidence behind it. Anyone with a genuine concern about methylation status would be better served by measuring homocysteine, which is a routine test with established reference ranges.
Is sublingual NMN better than capsules?
Sublingual products claim to bypass first-pass metabolism, and no human trial has compared sublingual against oral NMN on blood NAD+ or on anything else. The trials that produced the evidence behind this category used oral administration. Paying a premium for a delivery route with no comparative data, in a category where the underlying benefit is itself unsettled, is a weak use of money. Our NMN versus NR page covers what the trials measured.
Can you take NMN and NR together?
Nothing prevents it, and no trial has tested the combination. Both raise blood NAD+ through overlapping pathways, so the likely result is a more expensive way to reach a level either one reaches alone. If you are choosing between them, the differences that matter are regulatory history, third-party testing and price per gram rather than the theoretical advantage of stacking them.
Related
- NMN vs NR: which precursor has the evidence
- NMN side effects: what the trials reported
- Homocysteine: the methylation marker you can actually test
- Senolytics: the adjacent longevity supplement category
- Creatine for longevity: a supplement with outcome evidence
- Supplements hub: how we rank the evidence tiers